查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2138153

再生醫學和幹細胞療法市場預測至2034年—按療法、細胞來源、材料、應用、最終用戶和地區分類的全球分析

Regenerative Medicine & Stem Cell Therapy Market Forecasts to 2034 - Global Analysis By Therapy Type (Stem Cell Therapy, Gene Therapy, Tissue Engineering and Immunotherapy), Cell Source, Material, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球再生醫學和幹細胞治療市場規模將達到 399 億美元，並在預測期內以 18.2% 的複合年成長率成長，到 2034 年將達到 1520 億美元。

再生醫學和幹細胞療法旨在利用先進的細胞和再生醫學技術來修復受損或病變的組織和身體機能。其主要領域包括支持組織修復和再生的幹細胞療法、組織工程、生物材料和基因療法。研究和臨床試驗的進展正在拓展其在癌症、整形外科疾病、心血管疾病、神經系統疾病和傷口管理等領域的應用範圍。細胞處理、可擴展生產和監管流程的進步正在進一步加速再生醫學技術從實驗研究轉化為更廣泛的臨床應用。

根據世界衛生組織（世衛組織）的數據，2021年至少有4,300萬人死於非傳染性疾病，佔全球整體非疫情死亡總數的75%。心血管疾病、癌症、糖尿病和慢性呼吸系統疾病帶來的巨大負擔，為先進療法的持續研發提供了至關重要的醫學背景。

對再生醫學的需求日益成長

隨著醫療保健專業人員和研究人員探索修復和替換受損組織的方法，人們對再生醫學的興趣日益濃厚，推動了市場擴張。慢性病、創傷、退化性疾病和老齡化相關疾病負擔的加重，加速了細胞療法的發展。幹細胞技術正被研究用於整形外科、癌症治療、循環系統疾病、神經系統疾病和傷口管理等領域的潛在應用。持續的臨床研究、人們對再生醫學認知的不斷提高以及對創新醫療技術的投資，都在促進再生療法解決方案的開發和商業化。

再生醫學高成本

再生醫學及其生產製造的高成本會限制市場擴張和患者獲取治療的機會。細胞療法需要專門的設施、訓練有素的專業人員、先進的設備、嚴格的品質標準和複雜的生產流程。個人化療法還可能產生額外的細胞採集、處理、儲存、檢測和給藥費用。因此，治療的總成本對患者和醫療機構而言都可能相當高昂。新興療法的保險報銷不足或有限也可能構成進一步的障礙，尤其是在治療費用高昂或療法仍處於臨床開發或監管評估階段時。

再生醫學與尖端技術的融合

將再生醫學與新興技術結合，為開發精準先進的療法創造了新的機會。幹細胞研究將與組織工程、生物材料、基因編輯、 3D生物列印和人工智慧等領域日益緊密地融合在一起。生物列印技術將使研究人員能夠建造具有可控設計的組織結構，而先進的分析工具則可以支援研究、品質評估和生產製造。生物技術公司、大學、醫療機構和研究機構之間的合作將促進創新，並加速下一代再生醫學技術從基礎研究轉化為臨床應用的。

對倫理和社會接受度的擔憂

倫理考量和公眾認知差異可能對再生醫學和幹細胞治療市場構成挑戰，尤其是涉及胚胎幹細胞、基因改造或複雜細胞工程時。各國倫理框架和政策各不相同，可能會影響研發和臨床開發。關於知情同意、細胞捐贈、長期療效以及生物材料使用等方面的問題，可能會導致更嚴格的監管。圍繞特定幹細胞應用的社會爭議也會影響患者的信任度、研究參與度、投資決策以及再生醫學技術的更廣泛的商業化進程。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對再生醫學和幹細胞治療市場造成了暫時性的影響，包括臨床試驗延期、實驗室活動中斷、選擇性治療延遲以及病患招募困難。醫療資源向疫情應對的轉移也影響了研究活動以及專用材料和設備的供應鏈。同時，針對新冠併發症的幹細胞療法研究引起了科學界的更多關注。隨著醫療系統的恢復，延期的研究計畫重新啟動，投資增加，各機構繼續研發細胞療法，再生醫學所有應用領域的研發活動再次活性化起來。

在預測期內，幹細胞治療領域預計將佔據最大的市場規模。

由於其廣泛的治療範圍以及研發投入，預計幹細胞療法領域將在預測期內佔據最大的市場佔有率。幹細胞具有分化成各種特化細胞的能力，可用於修復、再生或取代受損組織。目前，幹細胞在腫瘤學、整形外科、心血管疾病、神經系統疾病和創傷護理等領域的應用研究正在不斷深入。幹細胞的採集、培養、分化、儲存和治療給藥技術的進步，進一步推動了創新，並擴大了幹細胞療法的潛在臨床應用範圍。

在預測期內，合約研究組織 (CRO) 領域預計將呈現最高的複合年成長率。

在預測期內，受外包研究、臨床前評估、臨床試驗管理、法規支援和專業實驗室服務需求不斷成長的推動，合約研究組織 (CRO) 領域預計將呈現最高的成長率。開發再生醫學的公司可以利用 CRO 獲取技術專長、先進的檢測設施和成熟的研究基礎設施，同時減少建立大規模內部系統的需求。幹細胞和細胞療法的日益複雜化也推動了外部合作。因此，生物技術公司與 CRO 之間的合作正在擴展研究能力，並促進再生醫學的發展。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的生物技術基礎設施、活躍的臨床研究活動以及細胞和基因療法的強勁發展。該地區擁有許多研究機構、專業醫療設施、生技公司和完善的監管機制。對再生醫學研究和生產的持續投入正在增強其治療生態系統。不斷擴大的臨床試驗、技術的進步以及再生醫學可及性的提高，進一步鞏固了北美在全球再生醫學領域的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的改善、生物技術投資的增加以及臨床研究的拓展。政府的支持性政策和不斷完善的法規結構正在加速中國、日本、韓國和印度的細胞療法發展。慢性病負擔的加重以及對先進療法日益成長的需求也推動了市場擴張。此外，該地區還受益於研發能力的提升、生產基礎設施的完善以及醫療機構、生物技術公司和研究機構之間廣泛合作的加強。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性評估）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球再生醫學與幹細胞療法市場：依療法類型分類

  • 幹細胞療法
  • 基因治療
  • 組織工程
  • 免疫療法

第6章：全球再生醫學和幹細胞療法市場：依細胞來源分類

  • 自體細胞
  • 同種異體細胞
  • 異質細胞
  • 誘導性多功能幹細胞（iPS細胞）

第7章 全球再生醫學和幹細胞療法市場：依材料分類

  • 生物材料和支架
  • 生物反應器和培養系統
  • 冷凍保存與細胞庫技術
  • 3D生物列印

第8章 全球再生醫學和幹細胞治療市場：按應用領域分類

  • 肌肉骨骼疾病
  • 神經病變
  • 心血管疾病
  • 腫瘤學
  • 皮膚科和創傷治療
  • 眼科

第9章 全球再生醫學和幹細胞治療市場：按最終用戶分類

  • 醫院和診所
  • 學術研究機構
  • 生物技術和製藥公司
  • 受託研究機構（CRO）

第10章 全球再生醫學和幹細胞治療市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Vericel Corporation
  • Mesoblast Limited
  • Takeda Pharmaceutical Company Limited
  • MEDIPOST Co., Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Anterogen Co., Ltd.
  • Stryker Corporation
  • Organogenesis Holdings Inc.
  • MiMedx Group, Inc.
  • Integra LifeSciences Holdings Corporation
  • Smith & Nephew plc
  • Zimmer Biomet Holdings, Inc.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Vertex Pharmaceuticals Incorporated
  • Pluri Inc.
  • Fate Therapeutics, Inc.
  • Holostem Terapie Avanzate Srl
Product Code: SMRC39753

According to Stratistics MRC, the Global Regenerative Medicine & Stem Cell Therapy Market is accounted for $39.9 billion in 2026 and is expected to reach $152.0 billion by 2034 growing at a CAGR of 18.2% during the forecast period. Regenerative Medicine & Stem Cell Therapy aims to restore damaged or diseased tissues and biological functions using advanced cellular and regenerative approaches. Key areas include stem cell-based treatments, tissue engineering, biomaterials, and gene therapies that support tissue repair and regeneration. Research progress and clinical studies are expanding applications in cancer, orthopedic conditions, cardiovascular diseases, neurological disorders, and wound management. Advances in cell processing, scalable manufacturing, and regulatory pathways are further supporting the movement of regenerative medicine technologies from experimental research toward broader clinical use.

According to the World Health Organization (WHO), noncommunicable diseases caused at least 43 million deaths in 2021, representing 75% of non-pandemic-related deaths globally. The substantial burden of cardiovascular diseases, cancers, diabetes, and chronic respiratory diseases provides an important medical context for continued development of advanced therapeutic approaches.

Market Dynamics:

Driver:

Rising demand for regenerative treatments

Growing interest in regenerative therapies is supporting market expansion as healthcare providers and researchers explore methods focused on repairing or replacing damaged tissues. The increasing burden of chronic illnesses, injuries, degenerative diseases, and age-associated conditions is encouraging development of cell-based therapeutic approaches. Stem cell technologies are being studied for potential use in orthopedic care, cancer treatment, cardiovascular medicine, neurological disorders, and wound management. Continued clinical investigations, increasing awareness of regenerative approaches, and investment in innovative healthcare technologies are collectively contributing to the development and commercialization of regenerative treatment solutions.

Restraint:

High cost of regenerative therapies

High costs associated with regenerative treatments and their production can limit market expansion and patient access. Cell-based therapies require specialized facilities, trained professionals, sophisticated equipment, strict quality standards, and complex production procedures. Personalized treatments may also generate additional costs for collecting, processing, storing, testing, and administering cells. Consequently, overall therapy expenses can become substantial for patients and healthcare institutions. Inadequate or limited reimbursement for emerging treatments can create another barrier, particularly when therapies are costly or still progressing through clinical development and regulatory evaluation.

Opportunity:

Integration of regenerative medicine with advanced technologies

Combining regenerative medicine with emerging technologies can create new opportunities for developing precise and sophisticated therapies. Stem cell research can increasingly intersect with tissue engineering, biomaterials, gene editing, three-dimensional bioprinting, and artificial intelligence. Bioprinting technologies may enable researchers to construct tissue structures with controlled designs, while advanced analytical tools can support research, quality assessment, and manufacturing. Partnerships between biotechnology firms, universities, healthcare institutions, and research organizations can strengthen innovation and facilitate the progression of next-generation regenerative medicine technologies from laboratory research toward clinical applications.

Threat:

Ethical and public acceptance concerns

Ethical considerations and varying public perceptions may create challenges for the Regenerative Medicine & Stem Cell Therapy Market, especially where embryonic stem cells, genetic modification, or complex cellular engineering are involved. Different countries maintain varying ethical frameworks and policies, potentially affecting research and clinical development. Questions surrounding informed consent, cell donation, long-term outcomes, and biological material use can lead to greater regulatory scrutiny. Public controversies involving particular stem cell applications may also influence patient confidence, research participation, investment decisions, and the broader commercialization of regenerative medicine technologies.

Covid-19 Impact:

The COVID-19 pandemic temporarily affected the Regenerative Medicine & Stem Cell Therapy Market through postponed clinical trials, disrupted laboratory activities, delayed elective treatments, and difficulties recruiting patients. Shifts in healthcare resources toward pandemic management also affected research operations and supply chains for specialized materials and equipment. At the same time, investigations into stem-cell-based treatments for COVID-19 complications generated additional scientific attention. Following healthcare-system recovery, delayed research programs restarted, investments strengthened, and organizations continued advancing cellular therapies, supporting renewed development activity across regenerative medicine applications.

The stem cell therapy segment is expected to be the largest during the forecast period

The stem cell therapy segment is expected to account for the largest market share during the forecast period because of its wide therapeutic scope and substantial research focus. Stem cells possess the ability to develop into specialized cells, making them valuable for repairing, regenerating, or replacing damaged tissues. Applications are being investigated in oncology, orthopedics, cardiovascular conditions, neurological disorders, and wound care. Progress in stem cell collection, cultivation, differentiation, storage, and therapeutic delivery is further supporting innovation and broadening the potential clinical use of stem cell-based treatments.

The contract research organizations (CROs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the contract research organizations (CROs) segment is predicted to witness the highest growth rate due to growing demand for outsourced research, preclinical evaluation, clinical trial management, regulatory assistance, and specialized laboratory services. Companies developing regenerative therapies can use CROs to obtain technical expertise, sophisticated testing facilities, and established research infrastructure while reducing the need for extensive internal capabilities. The increasing complexity of stem cell and cell-based therapies is encouraging external collaboration. Partnerships between biotechnology firms and CROs are consequently expanding research capabilities and helping advance regenerative medicine development.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by sophisticated biotechnology infrastructure, substantial clinical research activity, and strong development of cellular and gene-based therapies. The region has numerous research organizations, specialized healthcare facilities, biotechnology firms, and established regulatory mechanisms. Continued funding for regenerative medicine research and manufacturing is strengthening its therapeutic ecosystem. Expanding clinical investigations, technological progress, and broader access to regenerative treatments are further supporting North America's leading position within the global regenerative medicine landscape.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by improving healthcare infrastructure, greater biotechnology investment, and expanding clinical research. Supportive government programs and developing regulatory pathways are facilitating advancement of cellular therapies across China, Japan, South Korea, and India. Increasing chronic disease burdens and demand for advanced treatment options are contributing to market expansion. The region is also benefiting from stronger research capabilities, developing manufacturing infrastructure, and broader collaboration between healthcare institutions, biotechnology companies, and research organizations.

Key players in the market

Some of the key players in Regenerative Medicine & Stem Cell Therapy Market include Vericel Corporation, Mesoblast Limited, Takeda Pharmaceutical Company Limited, MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Anterogen Co., Ltd., Stryker Corporation, Organogenesis Holdings Inc., MiMedx Group, Inc., Integra LifeSciences Holdings Corporation, Smith & Nephew plc, Zimmer Biomet Holdings, Inc., Gilead Sciences, Inc., Novartis AG., Vertex Pharmaceuticals Incorporated, Pluri Inc., Fate Therapeutics, Inc. and Holostem Terapie Avanzate S.r.l.

Key Developments:

In June 2025, Smith+Nephew announce a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ever Orthopaedic Ambulatory Surgery Centre in the UK. Based in Poole, Dorset, the new centre will offer NHS and private patients access to leading joint repair and replacement technology for conditions such as rotator cuff repair, ACL reconstruction, knee and hip replacements, and foot & ankle/hand & wrist procedures.

In May 2025, Novartis has signed a strategic agreement with Shanghai Pharma to help sell the Swiss company's mature ophthalmic products in China. Novartis will leverage Shanghai Pharma's omni-channel integrated marketing services and broad market coverage capabilities to accelerate the reach of some Novartis drugs for ocular infections and glaucoma in smaller territories not currently targeted by Novartis.

Therapy Types Covered:

  • Stem Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Immunotherapy

Cell Sources Covered:

  • Autologous Cells
  • Allogeneic Cells
  • Xenogeneic Cells
  • Induced Pluripotent Stem Cells (iPSCs)

Materials Covered:

  • Biomaterials & Scaffolds
  • Bioreactors & Culture Systems
  • Cryopreservation & Cell Banking Technologies
  • 3D Bioprinting

Applications Covered:

  • Musculoskeletal Disorders
  • Neurological Disorders
  • Cardiovascular Disorders
  • Oncology
  • Dermatology & Wound Healing
  • Ophthalmology

End Users Covered:

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Biotechnology & Pharmaceutical Companies
  • Contract Research Organizations (CROs)

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Regenerative Medicine & Stem Cell Therapy Market, By Therapy Type

  • 5.1 Stem Cell Therapy
  • 5.2 Gene Therapy
  • 5.3 Tissue Engineering
  • 5.4 Immunotherapy

6 Global Regenerative Medicine & Stem Cell Therapy Market, By Cell Source

  • 6.1 Autologous Cells
  • 6.2 Allogeneic Cells
  • 6.3 Xenogeneic Cells
  • 6.4 Induced Pluripotent Stem Cells (iPSCs)

7 Global Regenerative Medicine & Stem Cell Therapy Market, By Material

  • 7.1 Biomaterials & Scaffolds
  • 7.2 Bioreactors & Culture Systems
  • 7.3 Cryopreservation & Cell Banking Technologies
  • 7.4 3D Bioprinting

8 Global Regenerative Medicine & Stem Cell Therapy Market, By Application

  • 8.1 Musculoskeletal Disorders
  • 8.2 Neurological Disorders
  • 8.3 Cardiovascular Disorders
  • 8.4 Oncology
  • 8.5 Dermatology & Wound Healing
  • 8.6 Ophthalmology

9 Global Regenerative Medicine & Stem Cell Therapy Market, By End User

  • 9.1 Hospitals & Clinics
  • 9.2 Academic & Research Institutes
  • 9.3 Biotechnology & Pharmaceutical Companies
  • 9.4 Contract Research Organizations (CROs)

10 Global Regenerative Medicine & Stem Cell Therapy Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Vericel Corporation
  • 13.2 Mesoblast Limited
  • 13.3 Takeda Pharmaceutical Company Limited
  • 13.4 MEDIPOST Co., Ltd.
  • 13.5 JCR Pharmaceuticals Co., Ltd.
  • 13.6 Anterogen Co., Ltd.
  • 13.7 Stryker Corporation
  • 13.8 Organogenesis Holdings Inc.
  • 13.9 MiMedx Group, Inc.
  • 13.10 Integra LifeSciences Holdings Corporation
  • 13.11 Smith & Nephew plc
  • 13.12 Zimmer Biomet Holdings, Inc.
  • 13.13 Gilead Sciences, Inc.
  • 13.14 Novartis AG
  • 13.15 Vertex Pharmaceuticals Incorporated
  • 13.16 Pluri Inc.
  • 13.17 Fate Therapeutics, Inc.
  • 13.18 Holostem Terapie Avanzate S.r.l.

List of Tables

  • Table 1 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Stem Cell Therapy (2023-2034) ($MN)
  • Table 4 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Gene Therapy (2023-2034) ($MN)
  • Table 5 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Tissue Engineering (2023-2034) ($MN)
  • Table 6 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 7 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Cell Source (2023-2034) ($MN)
  • Table 8 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Autologous Cells (2023-2034) ($MN)
  • Table 9 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Allogeneic Cells (2023-2034) ($MN)
  • Table 10 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Xenogeneic Cells (2023-2034) ($MN)
  • Table 11 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Induced Pluripotent Stem Cells (iPSCs) (2023-2034) ($MN)
  • Table 12 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Material (2023-2034) ($MN)
  • Table 13 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Biomaterials & Scaffolds (2023-2034) ($MN)
  • Table 14 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Bioreactors & Culture Systems (2023-2034) ($MN)
  • Table 15 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Cryopreservation & Cell Banking Technologies (2023-2034) ($MN)
  • Table 16 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By 3D Bioprinting (2023-2034) ($MN)
  • Table 17 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Application (2023-2034) ($MN)
  • Table 18 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Musculoskeletal Disorders (2023-2034) ($MN)
  • Table 19 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 20 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Cardiovascular Disorders (2023-2034) ($MN)
  • Table 21 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 22 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Dermatology & Wound Healing (2023-2034) ($MN)
  • Table 23 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Ophthalmology (2023-2034) ($MN)
  • Table 24 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 26 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 27 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Biotechnology & Pharmaceutical Companies (2023-2034) ($MN)
  • Table 28 Global Regenerative Medicine & Stem Cell Therapy Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.